Page last updated: 2024-08-22

lutetium and olaparib

lutetium has been researched along with olaparib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beerens, CE; de Jong, M; Doukas, M; Nonnekens, J; Suker, M; van Eijck, CH; van Gent, DC; van Kranenburg, M	1

Other Studies

1 other study(ies) available for lutetium and olaparib

Article	Year
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. Theranostics, 2016, Volume: 6, Issue:11 Topics: Bone Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Breaks, Double-Stranded; DNA, Neoplasm; Drug Synergism; Genomic Instability; Humans; Lutetium; Osteosarcoma; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents; Radioisotopes; Radiotherapy; Receptors, Somatostatin	2016

Article

Year

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.

Theranostics, 2016, Volume: 6, Issue:11

Topics: Bone Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Breaks, Double-Stranded; DNA, Neoplasm; Drug Synergism; Genomic Instability; Humans; Lutetium; Osteosarcoma; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents; Radioisotopes; Radiotherapy; Receptors, Somatostatin

2016